Following the November 4 regular-session close, Veracyte is trading at $43.50, down 17.17%, after management narrowed the upper end of its FY2026 revenue outlook, citing Decipher Prostate volumes below internal expectations.
- The Q3 report beat estimates, and Veracyte announced a $100 million share repurchase.
- Investors had focused on Decipher demand and volume expectations ahead of the report.